QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
NCT01029873
Completed
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose-escalation study of ALT-801 combined with cisplatin. The purpose of this study is to evaluate the safety, determine the Maximum-Tolerated Dose (MTD), and characterize the pharmacokinetic profile of ALT-801 given with cisplatin in patients who are chemotherapy naïve and have metastatic melanoma that is considered surgically incurable. The anti-tumor responses of ALT-801 with cisplatin will also be assessed in this tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2016
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +7 locations
Conditions: Metastatic Melanoma
Register for Updates
Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer
NCT00405405
Completed
To determine a safe and effective doses of two biologic drugs, erlotinib and bevacizumab when used with chemotherapy and radiation therapy in advanced head and neck cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/19/2016
Locations: Thomas Jefferson University, Philadelphia, Pennsylvania
Conditions: Head and Neck Cancer, Parotid Gland Cancer, Thyroid Gland Cancer, Melanoma, Stage IV Head and Neck Cancer
Register for Updates
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: City of Hope National Medical Center, Duarte, California +54 locations
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Register for Updates
A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer
NCT01450696
Terminated
This randomized, open-label, multicenter, international Phase IIIb study will compare the efficacy and safety of two Herceptin dosing regimens in combination with cisplatin/capecitabine chemotherapy in participants with HER2-positive metastatic gastric or gastro-esophageal junction adenocarcinoma. Participants who have not received prior treatment for metastatic disease will be randomized to receive Herceptin intravenously as either an 8-milligram per kilogram (mg/kg) loading dose followed by 6... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/05/2016
Locations: Not set, La Jolla, California +116 locations
Conditions: Gastric Cancer
Register for Updates
A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer
NCT01496742
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of RO5490258 (MetMab) in combination with either of two backbone chemotherapy regimens in the first-line setting in patients with incurable Stage IIIB or IV non-squamous non-small cell lung cancer. In Cohort 1, patients will be randomized to receive 4 cycles of bevacizumab (Avastin) 15 mg/kg iv, paclitaxel 200 mg/m2 iv, platinum (cisplatin/carboplatin) iv plus either MetMab 15 mg/kg iv or p... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/21/2016
Locations: Not set, Huntsville, Alabama +86 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)
NCT00094497
Completed
The purpose of this study is to determine whether treatment with etoposide, doxorubicin, cisplatin and mitotane (EDP/M) prolongs survival as compared to streptozotocin and mitotane (Sz/M) in patients with advanced adrenocortical carcinoma (ACC) whose disease is not amenable to complete surgical resection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2016
Locations: National Cancer Institute - Center for Cancer Research, Bethesda, Maryland +31 locations
Conditions: Carcinoma, Adrenal Cortical
Register for Updates
Gemzar, Cisp, Sunitinib Urothelial Ca
NCT00821327
Completed
The primary objective of this nonrandomized Phase II study is to evaluate the objective response rate (ORR, CR+PR) in patients with advanced/metastatic UC treated with the combination of gemcitabine, cisplatin, and sunitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Arizona Oncology Associates, Tucson, Arizona +47 locations
Conditions: Urothelial Cancer
Register for Updates
Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma
NCT00808639
Completed
The purpose of this research study is to test the effectiveness of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) in combination with pegfilgrastim followed by radical surgery in patients with muscle-invasive urothelial carcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/09/2016
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +3 locations
Conditions: Bladder Cancer, Muscle-invasive Bladder Cancer
Register for Updates
A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
NCT01661114
Completed
Multi-agent chemotherapy has value for patients with advanced pancreatic-biliary cancers leading to responses in a substantial minority and increasing survival. The use of the FOLFIRINOX regimen is limited by its' intensity and toxicity. Previous protocol and clinical experience within the University of Michigan Pancreatic Program leads to an expectation of tolerance and efficacy of the proposed regimen. Advantages of the proposed regimen relative to FOLFIRINOX include: 1. Substitution of gemci... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Conditions: Pancreatic Cancer, Biliary Cancer
Register for Updates
A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
NCT01519804
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: Not set, Huntsville, Alabama +68 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
NCT01194869
Terminated
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy work better. Additionally, by receiving chemotherapy before surgery, we will be able to determine if your cancer is responsive to chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2016
Locations: Grady Memorial Hospital, Atlanta, Georgia +2 locations
Conditions: Breast Cancer
Register for Updates
Preoperative Cisplatin in Early Stage Breast Cancer
NCT00148694
Completed
The purpose of this study is to find out what effects the preoperative therapy cisplatin will have on patients with early stage estrogen receptor-negative (ER-), progesterone receptor-negative (PR-), or HER-2 negative breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2016
Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +2 locations
Conditions: Breast Cancer
Register for Updates